| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/16/2013 | CN102871981A Tablet medicine compound containing levetiracetam |
| 01/16/2013 | CN102871966A Nano drug carrier particles for improving bioavailability of rapamycin and preparation method thereof |
| 01/16/2013 | CN102871960A Lentinan injection and preparation method thereof |
| 01/16/2013 | CN102870995A Chinese herbal medicine additive for pig feed |
| 01/16/2013 | CN102870971A Pig anti-stress preparation |
| 01/16/2013 | CN102441000B Anti-cancer anti-disease buccal tablet |
| 01/16/2013 | CN102283951B Chinese medicinal composition for treating anaphylactoid purpura and thrombocytopenic purpura |
| 01/16/2013 | CN102247403B Liquid nanometer selenium and preparation method thereof |
| 01/16/2013 | CN102228469B Nano-selenium particles and preparation method thereof |
| 01/16/2013 | CN102204946B Chinese lobelia polysaccharide extracted from Chinese lobelia and application thereof |
| 01/16/2013 | CN102161961B Health-care wine and preparation method thereof |
| 01/16/2013 | CN101948543B Fusion protein and coding gene and application thereof |
| 01/16/2013 | CN101921236B 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| 01/16/2013 | CN101306191B Use of TLR2 ligand PGN in treating metabolism syndrome |
| 01/15/2013 | US8354115 Binding proteins; vaccines; increased cytokine and antibody production |
| 01/15/2013 | CA2574664C Compound formulations of 2-amino-1,3-propanediol compounds |
| 01/15/2013 | CA2524161C Pyridinyl acetonitriles |
| 01/15/2013 | CA2461710C Incapacitated whole-cell immunogenic bacterial compositions |
| 01/15/2013 | CA2460269C Alphavirus replicon vector systems |
| 01/15/2013 | CA2424607C Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 01/10/2013 | WO2013006505A1 Use of anti-cd83 agonist antibodies for treating autoimmune diseases |
| 01/10/2013 | WO2013006333A1 Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| 01/10/2013 | WO2013005873A1 An antibody inducing antigen-specific t cell tolerance and use thereof |
| 01/10/2013 | WO2013005755A1 Methylpiperidine derivative |
| 01/10/2013 | WO2013005698A1 Biological inorganic compound complex having reduced oxygen and high reducing ability |
| 01/10/2013 | WO2013005603A1 Agent for prevention and/or treatment of allergic inflammation in conjunctiva |
| 01/10/2013 | WO2013004984A1 Tricyclic compounds for use as kinase inhibitors |
| 01/10/2013 | WO2013004190A1 Amino-propylene-glycol derivatives, preparation method and pharmaceutical composition and use thereof |
| 01/10/2013 | WO2013003899A1 Methods of treating or preventing rheumatic disease |
| 01/10/2013 | WO2012123493A3 Isoxazolidine derivatives |
| 01/10/2013 | WO2012069658A8 Immunomodulatory compositions comprising hydralazine for the treatment of gastrointestinal disorders |
| 01/10/2013 | US20130012922 Compositions and methods for the treatment of cancer |
| 01/10/2013 | US20130012692 Sodium channel blockers |
| 01/10/2013 | US20130012583 Vinyl substituted fatty acids |
| 01/10/2013 | US20130012575 Plant extract from low-thc cannabis for the treatment of disease |
| 01/10/2013 | US20130012571 Organic Compositions to Treat Beta-ENaC-Related Diseases |
| 01/10/2013 | US20130012567 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/10/2013 | US20130012564 SMAC Mimetic |
| 01/10/2013 | US20130012548 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds |
| 01/10/2013 | US20130012518 Bicyclic compounds and their uses as dual c-src / jak inhibitors |
| 01/10/2013 | US20130012517 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012515 Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012510 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 |
| 01/10/2013 | US20130012505 Benzonaphthyridinamines as autotaxin inhibitors |
| 01/10/2013 | US20130012504 Bi-functional quinoline analogs |
| 01/10/2013 | US20130012486 Combination steroid and glucocorticoid receptor antagonist therapy |
| 01/10/2013 | US20130012479 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012432 Peptides for Treatment of Obesity |
| 01/10/2013 | US20130011861 Modulators of p-selectin glycoprotein ligand 1 |
| 01/10/2013 | US20130011452 Topical foam composition |
| 01/10/2013 | US20130011443 Human respiratory syncytial virus vaccine |
| 01/10/2013 | US20130011439 Inactivated Bacterial Cell Formulation |
| 01/10/2013 | US20130011438 Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells |
| 01/10/2013 | US20130011437 Immune compositions for treating H. pylori infection |
| 01/10/2013 | US20130011434 Adjuvant diluents for live vaccines for pig diseases |
| 01/10/2013 | US20130011433 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 |
| 01/10/2013 | US20130011432 Disrupted adenovirus-based vaccine against drugs of abuse |
| 01/10/2013 | US20130011428 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/10/2013 | US20130011427 Flavivirus species-specific peptide tags for vaccine and diagnostic use |
| 01/10/2013 | US20130011425 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 01/10/2013 | US20130011424 Polyepitope constructs and methods for their preparation and use |
| 01/10/2013 | US20130011421 Triterpene saponins, methods of synthesis, and uses thereof |
| 01/10/2013 | US20130011417 Colchicine derivatives or pharmaceutically acceptable salts thereof, method for preparing said derivatives, and pharmaceutical composition comprising said derivatives |
| 01/10/2013 | US20130011415 Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof |
| 01/10/2013 | US20130011405 Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 01/10/2013 | US20130011401 Soluble proteins for use as therapeutics |
| 01/10/2013 | US20130011398 Serpin Fusion Polypeptides and Methods of Use Thereof |
| 01/10/2013 | US20130011395 Methods and compositions for treating autoimmune diseases or conditions |
| 01/10/2013 | US20130011376 Methods for Enhancing Natural Killer Cell Proliferation and Activity |
| 01/10/2013 | US20130011342 Surfactant-free, water-free formable composition and breakable foams and their uses |
| 01/10/2013 | CA2844532A1 An antibody inducing antigen-specific t cell tolerance and use thereof |
| 01/10/2013 | CA2841376A1 N-terminal deleted gp120 immunogens |
| 01/10/2013 | CA2840426A1 Use of anti-cd83 agonist antibodies for treating autoimmune diseases |
| 01/10/2013 | CA2839341A1 Methods of treating or preventing rheumatic disease |
| 01/10/2013 | CA2820977A1 Composition for use in treating and preventing inflammation related disorder |
| 01/09/2013 | EP2543730A1 Antibody constant region variant |
| 01/09/2013 | EP2543670A1 Pyrazolopyrimidine derivative |
| 01/09/2013 | EP2543381A1 Immunoglobulin a secretion promoter |
| 01/09/2013 | EP2542587A1 Antibodies against human csf-1r and uses thereof |
| 01/09/2013 | EP2542571A1 Oligomer-specific amyloid beta epitope and antibodies |
| 01/09/2013 | EP2542554A1 Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| 01/09/2013 | EP2542539A1 Tetrazole compounds which selectively modulate the cb2 receptor |
| 01/09/2013 | EP2542537A1 Novel compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (ror gamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune disease |
| 01/09/2013 | EP2542536A1 Morpholino substituted urea derivatives as mtor inhibitors |
| 01/09/2013 | EP2542535A1 Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms |
| 01/09/2013 | EP2542255A1 Methods and compositions for treating degos' disease |
| 01/09/2013 | EP2542238A1 Compounds for immunoproteasome inhibition |
| 01/09/2013 | EP2542080A1 Treatment of lupus arthritis using laquinimod |
| 01/09/2013 | EP2542078A1 Treatment of lupus nephritis using laquinimod |
| 01/09/2013 | CN1876657B Stabilization of macrolides |
| 01/09/2013 | CN102869666A Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| 01/09/2013 | CN102869663A Pyrazolopyrazine kinase inhibitors |
| 01/09/2013 | CN102869658A Modulators of fatty acid amide hydrolase |
| 01/09/2013 | CN102869368A Therapeutic use of the beta2m protein |
| 01/09/2013 | CN102869367A Novel cyclic peptides |
| 01/09/2013 | CN102869366A Prevention and treatment of allergic diarrhoea |
| 01/09/2013 | CN102869365A Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders |
| 01/09/2013 | CN102869353A Treatment of autoimmune disease |
| 01/09/2013 | CN102866119A Biological activity detection method of protein of flagellin protein derivative of salmonella and application thereof |
| 01/09/2013 | CN102864152A Immunostimulation characteristic of oligonucleotide-based compound comprising modified immunostimulation dinucleotide |